Which of the following medications targets homozygous hypercholesterolemia?

Which of the following medications targets homozygous hypercholesterolemia?

• A. Leqvio
• B. Evkeeza
• C. Nexletol
• D. Vascepa

Answer: (B)

B. Evkeeza is the correct answer because it is specifically designed to treat patients with homozygous familial hypercholesterolemia (HoFH). This condition is characterized by extremely high cholesterol levels due to genetic factors, and Evkeeza aims to reduce low-density lipoprotein (LDL) cholesterol by inhibiting the protein involved in the body's cholesterol metabolism, thereby helping manage this severe form of hypercholesterolemia. In contrast, while the other medications mentioned have roles in lipid management, they are not specifically approved for treating homozygous hypercholesterolemia. Leqvio, for instance, is used for lowering cholesterol but is focused on those who may have elevated cholesterol levels due to other cardiovascular factors. Nexletol also helps manage cholesterol levels but is not directed at the HoFH population. Vascepa (icosapent ethyl) primarily focuses on reducing cardiovascular risk in patients with elevated triglycerides rather than directly targeting LDL cholesterol in HoFH. Thus, Evkeeza stands out as the specific treatment for this genetic condition.

B. Evkeeza is the correct answer because it is specifically designed to treat patients with homozygous familial hypercholesterolemia (HoFH). This condition is characterized by extremely high cholesterol levels due to genetic factors, and Evkeeza aims to reduce low-density lipoprotein (LDL) cholesterol by inhibiting the protein involved in the body's cholesterol metabolism, thereby helping manage this severe form of hypercholesterolemia.

In contrast, while the other medications mentioned have roles in lipid management, they are not specifically approved for treating homozygous hypercholesterolemia. Leqvio, for instance, is used for lowering cholesterol but is focused on those who may have elevated cholesterol levels due to other cardiovascular factors. Nexletol also helps manage cholesterol levels but is not directed at the HoFH population. Vascepa (icosapent ethyl) primarily focuses on reducing cardiovascular risk in patients with elevated triglycerides rather than directly targeting LDL cholesterol in HoFH. Thus, Evkeeza stands out as the specific treatment for this genetic condition.